Considerations for Microbiological Control Strategy during Oligonucleotide Drug Substance Manufacturing
Organic Process Research & Development · 19.12.2025 · 29 (12) · 3013-3027
DOI: 10.1021/acs.oprd.5c00317 ↗Kurz gefasst
Fachartikel in der Zeitschrift Organic Process Research & Development, online erschienen am 29.11.2025. Verfasst von Deborah Allen und 17 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Allen, D., Arts, R., Belin, G., Borna, M., Coffin, C., Drinkwater, S., Jehle, P., Johnson, J., Nuydens, A., Olbrich, M., Ortiz, A. R., Ozdemir, M., Quinn, A., Seyberth, T., Smith, P. D., Tremmel, S., Venkatram, B., & Willis, J. (2025). Considerations for Microbiological Control Strategy during Oligonucleotide Drug Substance Manufacturing. Organic Process Research & Development, 29(12), 3013-3027. https://doi.org/10.1021/acs.oprd.5c00317
Vancouver
Allen D, Arts R, Belin G, Borna M, Coffin C, Drinkwater S, et al. Considerations for Microbiological Control Strategy during Oligonucleotide Drug Substance Manufacturing. Organic Process Research & Development. 2025;29(12):3013-3027. doi:10.1021/acs.oprd.5c00317
BibTeX
@article{Allen2025,
author = {Allen, Deborah and Arts, Rick and Belin, Gamze and Borna, Mandana and Coffin, Chris and Drinkwater, Sophie and Jehle, Peter and Johnson, Joyce and Nuydens, Anja and Olbrich, Martin and Ortiz, Aura R. and Ozdemir, Mahir and Quinn, Andrew and Seyberth, Tobias and Smith, Peter D. and Tremmel, Sandra and Venkatram, Bharath and Willis, Jonathan},
title = {Considerations for Microbiological Control Strategy during Oligonucleotide Drug Substance Manufacturing},
journal = {Organic Process Research & Development},
year = {2025},
volume = {29},
number = {12},
pages = {3013--3027},
doi = {10.1021/acs.oprd.5c00317}
}
EUVIMED